These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 22327246)

  • 1. Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.
    De Luca A; Marazzi MC; Mancinelli S; Ceffa S; Altan AM; Buonomo E; Prosperi MC; Pedruzzi B; Noorjehan AM; Scarcella P; Liotta G; Palombi L
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):236-44. PubMed ID: 22327246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.
    Hamers RL; Schuurman R; Sigaloff KC; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Wit FW; van Vugt M; Stevens WS; de Wit TF;
    Lancet Infect Dis; 2012 Apr; 12(4):307-17. PubMed ID: 22036233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability.
    Palombi L; Marazzi MC; Guidotti G; Germano P; Buonomo E; Scarcella P; Doro Altan A; Zimba Ida V; San Lio MM; De Luca A;
    Clin Infect Dis; 2009 Jan; 48(1):115-122. PubMed ID: 20380075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.
    Breton G; Lewden C; Spire B; Salmon D; Brun-Vézinet F; Duong M; Allavena C; Leport C; Salamon R;
    HIV Med; 2007 Apr; 8(3):164-70. PubMed ID: 17461860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
    Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
    Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to second-line ART in relation to mortality in a large Tanzanian HIV cohort.
    Hawkins C; Hertzmark E; Spiegelman D; Muya A; Ulenga N; Kim S; Khudyakov P; Christian B; Sando D; Aris E; Fawzi W
    J Antimicrob Chemother; 2017 Jul; 72(7):2060-2068. PubMed ID: 28387836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.
    May M; Boulle A; Phiri S; Messou E; Myer L; Wood R; Keiser O; Sterne JA; Dabis F; Egger M;
    Lancet; 2010 Aug; 376(9739):449-57. PubMed ID: 20638120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.
    Schoffelen AF; Wensing AM; Tempelman HA; Geelen SP; Hoepelman AI; Barth RE
    PLoS One; 2013; 8(3):e58526. PubMed ID: 23505529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating loss to follow-up in estimates of survival among HIV-infected individuals in sub-Saharan Africa enrolled in antiretroviral therapy programs.
    Verguet S; Lim SS; Murray CJ; Gakidou E; Salomon JA
    J Infect Dis; 2013 Jan; 207(1):72-9. PubMed ID: 23100567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
    Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
    Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality after failure of antiretroviral therapy in sub-Saharan Africa.
    Keiser O; Tweya H; Braitstein P; Dabis F; MacPhail P; Boulle A; Nash D; Wood R; Lüthi R; Brinkhof MW; Schechter M; Egger M;
    Trop Med Int Health; 2010 Feb; 15(2):251-8. PubMed ID: 20003034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.
    Fox MP; Cutsem GV; Giddy J; Maskew M; Keiser O; Prozesky H; Wood R; Hernán MA; Sterne JA; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):428-37. PubMed ID: 22433846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.
    Sigaloff KC; Hamers RL; Wallis CL; Kityo C; Siwale M; Ive P; Botes ME; Mandaliya K; Wellington M; Osibogun A; Stevens WS; van Vugt M; de Wit TF;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):23-31. PubMed ID: 21694603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
    Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
    Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
    Gianotti N; Lorenzini P; Cozzi-Lepri A; De Luca A; Madeddu G; Sighinolfi L; Pinnetti C; Santoro C; Meraviglia P; Mussini C; Antinori A; d'Arminio Monforte A;
    J Antimicrob Chemother; 2019 Sep; 74(9):2732-2741. PubMed ID: 31173639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.
    Shroufi A; Van Cutsem G; Cambiano V; Bansi-Matharu L; Duncan K; Murphy RA; Maman D; Phillips A
    AIDS; 2019 Aug; 33(10):1635-1644. PubMed ID: 31305331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
    Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
    J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.